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Abstract
Neuropathic pain is clinically described as pain caused by a lesion or disease of the somato-
sensory nervous system. The aim of this study was to assess the validity of the Dutch ver-
sion of the DN4, in a cross-sectional multicentre design, as a screening tool for detecting a
neuropathic pain component in a large consecutive, not pre-stratified on basis of the target
outcome, population of patients with chronic pain. Patients’ pain was classified by two inde-
pendent (pain-)physicians as the gold standard. The analysis was initially performed on the
outcomes of those patients (n = 228 out of 291) in whom both physicians agreed in their
pain classification. Compared to the gold standard the DN4 had a sensitivity of 75% and
specificity of 76%. The DN4-symptoms (seven interview items) solely resulted in a sensitiv-
ity of 70% and a specificity of 67%. For the DN4-signs (three examination items) it was
respectively 75% and 75%. In conclusion, because it seems that the DN4 helps to identify a
neuropathic pain component in a consecutive population of patients with chronic pain in a
moderate way, a comprehensive (physical-) examination by the physician is still obligate.
Introduction
Neuropathic pain is described as pain caused by a lesion or disease of the somatosensory
nervous system and requires a demonstrable lesion or a disease that satisfies established neuro-
logical diagnostic criteria[1]. Moreover, neuropathic pain is a clinical description and not a
diagnosis[1]. In daily clinical practice it is to our opinion more appropriate to speak of a pres-
ent neuropathic pain component (present NePC) or absent neuropathic pain component
(absent NePC)[2, 3]. This because the pain experienced by the patient in the clinical context
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may be caused by both neuropathic- as well as nociceptive mechanisms (also known as ‘mixed
pain’)[2, 4–6]. The main features of neuropathic pain components are, in clinical practice, the
painful signs and symptoms in a region of altered sensations (numbness or increased sensitiv-
ity)[6]. The assessment of neuropathic pain is nowadays primarily based on history and physi-
cal examination including (bedside-)sensory testing[7–9] to assess patients’ pain.
Since current pharmacological treatment of patients with and without a NePC differs
strongly, a correct pain classification is imperative[7, 10]. The availability of a simple and vali-
dated screening tool to determine the presence of NePC for clinical triage and epidemiological
purposes can assist in detection of NePC[7, 8, 11–16]. This is especially true when this tool can
be used by non pain specialists.
The original French validation study of the ‘Douleur Neuropathique en 4 Questions’ (DN4)
[17] was performed in patients with neuropathic pain resulting from, for example, nerve
trauma or post herpetic neuralgia. Patients with non-neuropathic pain were, amongst other
diagnoses, suffering from osteoarthritis. All included patients had pain of at least a moderate
severity ( 40 on a 100mm visual analogue scale). Pain classification in this study was based
on medical history, physical examination, electromyography and/or imaging by two indepen-
dently working physicians. DN4 application resulted in a sensitivity of 83% and a specificity
of 90%[17]. As indicated in a systematic review by Mathieson et al[16] the classification of a
NePC may differ between clinicians and may be more difficult when there are patients
included with mixed pain and with all levels of pain. This reflects the patient population in a
daily clinical practice, but might have an influence on the validity. Moreover, the accuracy of
screening tools is dependent on the standardization of the assessment strategy[18]. Transla-
tion/ cross-cultural adaptation and/or validation of the DN4 was performed in more than 75
languages[19–31].
The neuropathic pain special interest group (NeuPSIG) grading system[32] is developed by
Treede et al in 2008 and updated in 2016[33]. It is a system to help the clinician to determine
the certainty of the pain classification for the existence of a NePC in an individual patient:
non-neuropathic pain; possible, probable or definite neuropathic pain. The grading system is
suggested to be helpful in the assessment of the pain classification in clinical practice[34–38].
The aim of this study was to assess the validity and reliability of the DN4 as a screening tool
for use in daily outpatient practices to detect a NePC in a, not pre-stratified on the target out-
come, consecutive patient population having chronic pain syndromes due to low back and
leg pain (LBLP), neck-shoulder-arm-pain (NSAP) or pain of suspected neuropathic origin
(PSNO).
Methods
This validity and reliability study had a cross-sectional, longitudinal, research design with a
2-weeks and 3-months follow-up period. Comparisons were made between the DN4 (as a
whole and for the symptom questions and signs tests separately) and the classification of
patients’ pain by two, independently working, physicians (the gold standard) as well as with
the grading system.
The study was approved by the Committee on Research Involving Human Subjects region
Arnhem-Nijmegen, Nijmegen, the Netherlands, (dossier number: 2008/348; NL 25343.091.08)
which counts for participation of the Dutch academic pain centers (Radboud University Medi-
cal Center, Nijmegen; Utrecht University Medical Center, Utrecht; Erasmus Medical Center,
Rotterdam), Dutch non-academic pain centers (Bernhoven Ziekenhuis, Oss; St.Anna Zieken-
huis, Geldrop) and a Dutch non-academic department of neurology (Rijnstate Ziekenhuis,
Arnhem). Participation of Dutch non-academic pain center in Delft, the Netherlands (Reinier
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de Graaf gasthuis) was approved by Medisch Ethische Toestings Commissie Zuidwest Holland
(dossier number: 10–145). The study protocol was registered in the Dutch National Trial Reg-
ister (NTR3030).
We used the same methodology as in the published protocol [39] and as employed in a
simultaneous study regarding the validity of the PainDETECT (Timmerman et.al / Under
review by BMC Neurology).
Participants
Consecutive patients (first time visitors of the participating centers) without pre-stratification
based on the target outcome[40] were included in the study between October 2009 until July
2013. Patients were asked to participate by their doctor. Each patient signed informed consent
before participation in the study.
At that time, there was only a rough diagnosis: LBLP, NSAP or PSNO. Inclusion criteria:
Male and female adult patients (18 years of age) with chronic (3 months) LBLP or NSAP
radiating into respectively leg(s) or arm(s) or patients with chronic pain due to a PSNO (pain
associated with a lesion or disease of the peripheral somatosensory system). Exclusion criteria:
Patients diagnosed with malignancy; compression fractures; patients with diffuse pains (such
as fibromyalgia or ankylosing spondylitis); severe mental illness; chronic alcoholism or sub-
stance abuse; inability to fill in the questionnaire adequately or incapable of understanding the
Dutch language.
Physicians
The physicians (pain specialists, pain specialist fellows or neurologists always operating in
differently composed pairs) participating in this study were not selected on basis of age, experi-
ence as a physician or any other criteria. Classification of patients’ pain was based on the NeuP-
SIG guidelines on neuropathic pain assessment[7] and recorded as absent NePC or present
NePC. Pain classification was performed consecutively on the same patient by two physicians
and categorized afterwards in three groups: absent NePC, present NePC or ‘undetermined’ (i.e.
the pain classification of the two physicians was not the same). A full medical history and clini-
cal examination including sensory bedside examination (touch, pinprick, pressure, cold, heath
and temporal summation) was taken[7, 8, 39, 41, 42] and was considered to be the gold stan-
dard when assessed by two physicians. The NeuPSIG grading system[32, 33] was used as a sec-
ondary comparison with the outcome of the DN4 and was assessed by both the physicians
separately. The outcomes “probable” and “definite” were regarded as present NePC. “unlikely”
and “possible” as absent NePC[38, 43, 44]. The physicians worked independently of each other
and were blinded to the pain classification of the other physician. Each physician was allowed
to perform the clinical examination in the way he or she is used to do but were supported by a
standardized assessment form[39]. In this form, the pain score, a body map to indicate the
localization of patients pain, the sensory examination and the four questions of the grading sys-
tem had to be filled in by the physician. The participating physicians were trained in a stan-
dardized way (presentation about the study and the outcome parameters and a practical
training on how to use the (measurement) instruments), by the investigator (HT) or by a desig-
nated person on location before participation in the study. Practical training was focused on
the classification of NePC, the assessment of the grading system, the performance of bed-side
examination tests and the performance and assessment of the examination items of the DN4.
In this study, 62 physicians (pain specialist, pain specialist-fellow or neurologist) partici-
pated. The physicians who were classifying patients’ pain at the first session were called
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‘Physicians A’. The physicians who performed the classification at the second session, were
called ‘Physicians B’.
Measurements
Douleur Neuropathique en 4 questions (DN4). The DN4 [17, 20, 25] (Pfizer bv. Capelle
a/d IJssel, the Netherlands) consists of 10 items in total and is developed to screen for symp-
toms and signs of neuropathic pain resulting in a yes/no answer for the presence of neuropathic
pain. This instrument is divided into two questions (seven answers, DN4-symptoms: score
range 0–7) and two physical examination tests (three answers, DN4-signs: score range 0–3).
The examination items of the DN4 regarding the signs (hypoesthesia to touch, hypoesthesia to
prick and brushing) were incorporated in the sensory examination part of the standardized
assessment form and were carried out according the original publication by Bouhassira et al
[17]. This assessment form was filled in by both physicians separately. The seven symptom
items are consisting of characteristics (Burning, painful cold, electric shocks) and symptoms
(Tingling, pins and needles, numbness, and itching). The patient completed the DN4-symp-
toms directly after the clinical assessments by the physicians but without interference. The
researcher (HT) or a nurse was available for help in person or via telephone when it was not
clear fort the patient how to fill in the questionnaires.
The items of the DN4 are scored based on a yes (1 point) /no (0 points) answer. This leads
to a score range of 0–10 when the symptoms (range 0–7 points) as well as the signs (range 0–3
points) items are included. Values in the DN4 who were not filled in were considered as ‘no’ (0
points). However, in the reliability analysis these data were not incorporated.
Patient global impression of change (PGIC). The Patients Global Impression of Change
(PGIC)[11, 45–47] was used to assess the change of pain complaints, based on the patients’
own impression of change over time, during the follow-up period (7-points scale: Very much
improved-very much worse). Follow-up took place two weeks and three months after the ini-
tial visit. To compare the outcome of the DN4 in the follow-up period the pain complaints as
addressed by the patient had to be unchanged.
Time-line
All baseline measurements (the assessment by the physicians, the grading system by both phy-
sicians as well as filling in the questionnaires by the patient) took place on preferably the same
day. The PGIC [45–47] and the DN4-symptoms (sensory testing for the DN4-signs was not
performed) were sent to the patient after two weeks and three months with instructions how
to fill them in by mail. Also for the follow-up measurements help was available in person or via
telephone when it was not clear how to fill in the questionnaires.
Data
All data was collected on paper and stored by Radboudumc, Nijmegen, The Netherlands. Data
management and monitoring were performed within MACRO (MACRO, version 4.1.1.3720,
Infermed, London, United Kingdom). Data analysis and statistics was performed by use of Sta-
tistical Package for the Social Sciences (IBM SPSS statistics 22, SPSS Inc., Chicago, Illinois,
USA).
Statistical analysis
According to the power-calculation in the protocol 132 patients with LBLP, NSAP or PSNO
were needed such that the sample size contains adequate numbers of cases and controls[39].
The validity of the DN4 in patients with chronic pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0187961 November 30, 2017 4 / 21
Qualitative variables are presented as frequencies and percentages. The quantitative variables
are presented as mean and standard deviation (SD) or as median and inter quartile range
(IQR).
The agreement between any of the two combinations of the two observers (pain classifica-
tion by the physician and the outcome of the grading system) to establish a present NePC or
absent NePC, and of the DN4 (DN4 / DN4-symptoms / DN4-signs outcome) was evaluated by
use of Cohen’s kappa (K), prevalence index (Pi) and percentage of pair wise agreement (PA).
The categorization of the kappa values are, according to the categorization of observer agree-
ment by Landis and Koch[48], none beyond chance (K0.00); slight (K = 0.01–0.20); fair
(K = 0.21–0.40); moderate (K = 0.41–0.60); substantial (K = 0.61–0.80) and (almost) perfect
agreement (K = 0.81–1.00). A K 0.40 and a PA 70% is considered indicative of interob-
server reliability acceptable for use in clinical practice[48]. Moreover, also the interobserver
reliability of the examination items in the DN4-signs were tested.
Based on the classifications of the two physicians, all patients were categorized as absent
NePC, present NePC or ‘undetermined’ (i.e. the pain classification of the two physicians was
not the same).
Statistical significant differences between absent NePC and present NePC were determined
by use of students t-test (Interval scales), Mann-Whitney U-test groups (ordinal scales) or via
Chi2-test (nominal scale). The statistical significant differences between present NePC, absent
NePC and the Undetermined group was assessed by use of One-way ANOVA (with additional
Tukey’s studentized range post-hoc test) or Kruskal-Wallis test. Chi2 test was also used to ana-
lyze the nominal outcome scale of the DN4 regarding the three groups.
A factor analysis was used to study the structure of the DN4 in such a way that variables
that were thought to reflect a smaller number of underlying variables were observed. This
method was performed for all three versions of the DN4 (DN4; DN4-symptoms and
DN4-signs). Principal axis factoring was used as the extraction method. The varimax rotation
with Kaiser normalization was used. Extraction of the factors was based on Eigenvalues being
greater than 1.0. Cronbach’s alpha was used to calculate the internal consistency of the factors
constructed. The results are only shown for the Physicians A (the assessment of the patient by
the first physician). The outcomes by the Physicians B (the assessment of the patient by the sec-
ond physician) are shown in S1 Table. However, the conclusions, which are drawn, are identi-
cal for physicians A and for physicians B.
A receiver operating characteristic (ROC) curve was calculated for the DN4 and the DN4
signs by both the physicians A and B and for the DN4-symptoms as filled in by the patient.
The area under the curve (AUC) with 95% confidence interval was presented to indicate the
discriminatory power of the DN4 to discriminate patients by present NePC or absent NePC.
This dichotomy was based on the physicians’ assessment outcome or based on the grading sys-
tem outcome, respectively. The theoretical maximum of the AUC is 100%, indicating a perfect
discrimination and 50% is equal to tossing a coin. An AUC between 0.9 and 1 is considered to
be excellent, an AUC between 0.8 and 0.9 is good and between 0.7 and 0.8 is fair. An AUC
between 0.6 and 0.7 is considered to be poor. Between 0.5 and 0.6 the AUC is considered to be
failed[49–52]. The optimal cut-off point of the DN4 was calculated under the condition of
equal-costs of misclassification using the Youden-index. Sensitivity, specificity, positive and
negative predictive values and the likelihood ratio in the population in this study was calcu-
lated at this cut-off point. The outcome results were averaged between both physicians and the
95% confidence intervals were noted with respect to the lowest and highest level.
Clinimetrics of the DN4 based on both the physicians assessment and/or both the grading
system outcome were assessed for the DN4, the DN4-symptoms and for the DN4-signs items.
The validity of the DN4 in patients with chronic pain
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A screening tool for the presence of a NePC is considered valid if it has a high sensitivity, speci-
ficity, high positive predictive value and a high positive likelihood ratio [53].
Intraclass correlation (ICC) was used to assess reproducibility (‘test-retest reliability’) of the
DN4-symptoms between the predetermined time points (baseline versus two weeks & baseline
versus three months). Based on the guidelines by Cicchetti et al.[54, 55] an ICC <0.40 indi-
cates poor level of clinical significance. The level is fair when the ICC is between 0.40 and 0.59,
good between 060 and 0.74 and excellent when the ICC is between 0.75 and 1.00. To assess the
test-retest reliability patients’ pain should not have changed (outcome based on the PGIC)
because otherwise the ICC would not reflect the consistency of the DN4. Test-retest reliability
was assessed for those questionnaires returned within 7–21 days for the two weeks test-retest
reliability and 60–120 days for the three months test—retest reliability. The ICC and respon-
siveness of the DN4-symptoms was assessed at each point of measurement.
Two-tailed p-value below 0.05 was considered statistically significant.
Results
Patients
In this study 330 consecutive patients were assessed for eligibility (Fig 1). Of these, 291 partici-
pated in the study between October 2009 and July 2013. Two patients did not give their
informed consent. Exclusion (n = 37) was because of not fulfilling the in- and exclusion criteria
(n = 13): patients with LBLP or NSAP without radiating pain: n = 1; patients with less than 3
months pain complaints: n = 2; patients with pain with an oncological cause: n = 2; patients
with painful syndromes of unknown origin or associated with diffuse pains: n = 7; patients
with severe mental illness: n = 1; missing baseline measurements due to not returning ques-
tionnaires by the patient: n = 16; missing pain classification based on the grading system by
one physician (n = 5) or both the physicians (n = 3). 132 patients had LBLP with radiation in
Fig 1. Flow diagram for the outcome of the physicians assessment and the NeuPSIG grading system. Present
NePC: present neuropathic pain component; Undetermined: Both physicians disagree with each other about the existence
of a neuropathic pain component; Absent NePC: absent neuropathic pain component; n = total number of patients in
analysis PhA: Physicians assessment; GS: Neuropathic pain special interest group grading system (missing pain
classification based on the grading system: n = 8).
https://doi.org/10.1371/journal.pone.0187961.g001
The validity of the DN4 in patients with chronic pain
PLOS ONE | https://doi.org/10.1371/journal.pone.0187961 November 30, 2017 6 / 21
one or two legs (45.4%), 51 NSAP with radiation in one or both arms (17.5%) and 108 patients
(37.1%) had PSNO: 86 patients with pain after treatment for breast cancer (surgery and che-
motherapy and/or radiation therapy and/or hormonal therapy). Twenty-two patients had pain
for various reasons: peripheral nerve damage (n = 12), radicular pain (n = 3), polyneuropathy
(n = 3), CRPS (n = 2) and post stroke pain (n = 2). The gold standard for presence of the NePC
in this study was the concordant clinical opinion of both physicians. After pain classification
by two physicians, 170 patients were classified as present NePC, 58 as absent NePC and in 63
patients the two physicians made a different pain classification: ‘undetermined’. Using the
grading system, 139 patients were assigned as having a present NePC, 93 patients as absent
NePC and 51 patients were assigned as undetermined. The DN4 was full filled by the patients
at a median of one day (IQR 0–5 days) following the assessments by the physicians.
Clinical and social-demographic details of the 291 patients were analyzed based on their
pain classification. No statistically significant differences were found between present NePC
and absent NePC for gender, age, height, weight, BMI, medication and duration of pain. Also
no statistically significant difference was observed between absent NePC and present NePC
regarding current- worst and average pain (Table 1).
Table 1. Clinical and socio-demographic characteristics of the patients related to physicians agreement for the existence of a neuropathic pain
component.
NePC Absent Present Undetermined
N N P N P
Total number of patients 58 170 63
Gender 0.163c 0.164c
Male 25 (43%) 56 (33%) 17 (27%)
Female 33 (57%) 114 (67%) 46 (73%)
Age (Years) # 58 55 ± 12 170 56 ± 11 0.594a 63 58 ± 13 0.522d
Height (cm) # 55 172 ± 9 164 172 ± 8 0.845a 6 170 ± 9 0.250d
Weight (kg) # 55 84 ± 2 167 80 ±17 0.382a 6 80 ± 16 0.461d
BMI (kg/m2) # 54 28 ± 8 164 27 ±5 0.436a 6 27 ± 5 0.593d
Medication use^ 55 56.9% 168 66.1% 0.414c 61 57.4% 0.423c
Duration of pain (months) # 57 72 ± 90 169 60 ± 76 0.327a 62 49 ± 46 0.247d
Pain* (NRS; 0–10)
Current pain 57 5 (3–7) 167 6 (3–7) 0.577b 6 4 (1–7) 0.084e
Worst pain during the past four
weeks
57 8 (5–9) 167 8 (7–9) 0.371b 6 7 (5–8) 0.053e
Average pain during the past
four weeks
57 6 (3.5–7) 167 6 (5–8) 0.233b 6 6 (3–7) 0.018e
Classification for the existence of NePC is based on physicians assessment of the patients. NePC: neuropathic pain component; Absent: NePC is absent;
Present: NePC is present; Undetermined: both physicians disagree with each other about the existence of a neuropathic pain component; N: total number
of patients in analysis; n: number of patients;
^percentage;
#Standard deviation;
* Inter quartile range. A: physicians A; B: Physicians B; P value for significant difference between groups (P 0.05) by use of different analyse methods:
a: Students t-test;
b: Mann-Whitney U test;
c: Chi-square;
d: One-Way ANOVA;
e: Kruskal-Wallis test.
https://doi.org/10.1371/journal.pone.0187961.t001
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Reliability
The proportion of agreement after chance agreement is removed (Cohen’s Kappa, K) for the
classification of patients’ pain (absent NePC or present NePC) by the physicians was 0.49
(moderate), with a PA of 78.4% (Pi = 0.38; n = 291). For the classification of patients’ pain on
basis of the grading system K was 0.63 (good) and PA was 82% (Pi = 0.16; n = 283). The out-
come of K and PA regarding the DN4 compared to the outcome of the assessment by physi-
cians A was respectively 0.34 (fair) and 69.8% (Pi = 0.33; n = 275). Compared to the outcome
of the assessment by physicians B it was 0.33 (fair) and 69.2% (Pi = 0.30; n = 263). Comparing
the outcome of the DN4 to the outcome of the grading system, it was 0.35 (fair) and 69.1%
(Pi = 0.22; n = 272) for physicians A, and 0.32 (fair) and 67.3%(Pi = 0.19; n = 260) for physi-
cians B (Table 2). The interobserver reliability for ‘hypoesthesia to touch’ as well as for ‘brush-
ing’ was respectively K = 0.59 (moderate) (PA = 79.7%) and K = 0.53 (moderate)(PA = 76.6%).
The interobserver reliability for ‘hypoesthesia to prick’ was K = 0.21 (fair); PA = 87% (Table 3).
In 253 patients all the six outcome variables (two times the physicians’ assessment, two
times the grading system and The DN4 by physician A and DN4 by physician B was available.
In 83 patients (32.8%), the pain was classified as present NePC in all outcomes and in 22
patients (8.7%) it was six times negative, indicating absent NePC, so the agreement on all the
six measures was 41.5% (the percentage of agreement based on both the gold standards and
both the grading systems only was 56.9%).
Factor analysis
Table 4 shows the loading factor of the items of the DN4 according to the rotated component
matrix factor analysis with Kaiser normalization. The analysis was performed by use of the 10
questions in the DN4 and revealed a 4-factor solution explaining 59.3% of the variance for the
first physicians’ assessment (physicians A): Factor 1 included two items (hypoesthesia to
touch, brushing) indicating that there was an inter-relation between those items (Cronbach’s
α: 0.87). Factor 2 included three items (painful cold, tingling, hypoesthesia to prick) (Cron-
bach’s α: 0.37). Factor 3, consisted of four items (burning, electric shocks, pins and needles,
numbness); Cronbach’s α: 0.51). Factor 4 consisted of one item (itching) (Table 4). In the S1
Table we provided the factor analysis for both the physicians assessments (A & B), the DN4
symptoms solely and the DN4signs for both physicians’ assessments (A & B). Internal consis-
tency of all the components of the DN4 for the physicians A at baseline was assessed via Cron-
bach’s α: 0.57; for the physicians B it was 0.55. Cronbach’s α for DN4-symptoms was 0.52.
Cronbach’s α for the DN4-signs for A and B were respectively 0.68 and 0.66.
Items of the DN4
The DN4-symptoms (pain descriptors) burning, electric shocks, tingling, pins and needles,
and numbness were statistically significant associated (Chi2) with the classification by the phy-
sicians (absent NePC, present NePC or undetermined), p<0.05. The descriptors ‘painful cold’
(p = 0.210) and ‘itching’ (p = 0.409) were not associated with the outcome of the classification.
The DN4-signs (examination items) hypoesthesia to touch, pricking and brushing were statis-
tically significant associated (Chi2) with the classification by the physicians (absent NePC,
present NePC or undetermined), p<0.05.
The median of the total sum score of the DN4 for patients classified as absent NePC was 2,
the median for the DN4-symptoms items was 2 and for the DN4-signs items the median was
0; for patients classified as present NePC it was at median 5, 3 and 2, respectively. As calculated
based on the Kruskal-Wallis test there was for the sum scores of the DN4, the DN4-symptoms
items and the DN4-signs items a statistical significant difference between absent NePC and
The validity of the DN4 in patients with chronic pain
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present NePC (P<0.001), between present NePC and undetermined (P<0.001) and between
absent NePC and undetermined (P<0.001). In Table 5 the outcomes for all individual items
and the three DN4 scales (for physicians A as well as for physicians B) are presented according
to the pain classification by the physicians (Table 5).
Validity
We constructed ROC-curves for the DN4, the DN4-symptoms and the DN4-signs with respect
to the classification by physician A or B and according to the neuropathic pain grading system
Table 2. The kappa coefficient between the classification on basis of the assessment by the physicians, the grading systems, the DN4 and the
kappa coefficient between both physicians regarding the DN4-signs.
Classification physician
B
Grading
A
Grading
B
DN4
A
DN4
B
DN4
Symptoms
DN4-Signs
A
DN4-Signs
B
Classification physician
A
n 291 286 288 275 263 288 279 266
K 0.49 0.48 0.32 0.34 0.34 0.32 0.37 0.26
PA 78.4 76.2 67.4 69.8 70.0 67.4 70.3 64.4
Pi 0.38 0.32 0.26 0.33 0.31 0.26 0.30 0.30
Classification physician
B
n 286 288 275 263 288 279 266
K 0.38 0.48 0.33 0.33 0.21 0.39 0.37
PA 71.0 75.0 69.1 69.2 62.8 71.0 70.7
Pi 0.28 0.22 0.29 0.30 0.25 0.26 0.28
Grading A n 283 272 259 283 276 262
K 0.63 0.35 0.31 0.14 0.54 0.31
PA 82.0 69.1 67.2 58.6 77.5 67.2
Pi 0.16 0.22 0.23 0.19 0.19 0.21
Grading B n 272 260 285 276 263
K 0.29 0.32 0.13 0.53 0.45
PA 65.4 67.3 57.2 76.8 73.4
Pi 0.18 0.19 0.14 0.14 0.16
DN4 A n 257 275 275 257
K 0.76 0.62 0.52 0.29
PA 88.7 81.8 76.7 65.8
Pi 0.21 0.19 0.17 0.19
DN4 B n 263 257 263
K 0.65 0.40 0.45
PA 82.9 71.2 73.4
Pi 0.18 0.21 0.17
DN4 symptoms n 276 263
K 0.15 0.10
PA 58.7 56.3
Pi 0.17 0.16
DN4-Signs A n 260
K 0.55
PA 78.4
Pi 0.18
n = total number of patients in the analysis; K = Cohen’s kappa value; PA (%) = percentage of agreement between two outcome variables; Pi = Prevalence
index
https://doi.org/10.1371/journal.pone.0187961.t002
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by physician A or B and all the combinations (Concordant assessment by physicians A and B
together, concordant grading system by Physicians A and B together and concordant grading
system for Physicians A and B together with the concordant grading system by physicians A
and B). This because of the chosen gold standard and the grading system in which patients
were classified by two different physicians. This might have lead to differences in the outcomes
relative to the individual outcome by the physician. In Fig 2 the ROC-curve is displayed for the
DN4 (physicians A and physicians B), DN4-symptoms and the DN4-signs (physicians A and
physicians B) (Fig 2).
Table 3. The kappa coefficient between both physicians regarding the DN4-signs.
Hypoesthesia to touch
DN4-signs B
Hypoesthesia to prick
DN4-signs B
Brushing
DN4-signs B
Hypoesthesia to touch
DN4-signs A
n 222
K 0.59
PA 79.7
Pi 0.10
Hypoesthesia to prick
DN4-signs A
n 244
K 0.21
PA 87.3
Pi -0.82
Brushing
DN4-signs A
n 222
K 0.53
PA 76.6
Pi 0.11
n = total number of patients in the analysis; K = Cohen’s kappa value; PA (%) = percentage of agreement between two outcome variables; Pi = Prevalence
index
https://doi.org/10.1371/journal.pone.0187961.t003
Table 4. Loading factors of the items of the DN4 according to the rotated component matrix factor
analysis.
DN4 Component (Physicians A)
1 2 3 4
Burning 0.25 0.28 0.29 0.15
Painful cold 0.62
Electric shocks 0.72
Tingling 0.68
Pins and needles 0.35 0.45 0.27
Numbness 0.71
Itching 0.86
Hypoesthesia to touch 0.87
Hypoesthesia to prick 0.38 0.63
Brushing 0.90
Cronbach’s alpha 0.81 0.37 0.51
Loading factors < 0.25 are omitted to improve readability
https://doi.org/10.1371/journal.pone.0187961.t004
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Based on the gold standard the sensitivity of the DN4 was on average (at maximal Youden-
index, cut off point: 4/10) 75% (95% CI 0.68–0.81), specificity 76% (95% CI 0.61–0.86), positive
predictive value 92% and the positive likelihood ratio was 3.09 (95% CI 1.82–5.39) (Table 5; S2
Table). For patients with LBLP the sensitivity was on average 75% and specificity was on aver-
age 81%. For patients with NSAP the averaged sensitivity was 73% and the specificity was on
average 72%. For patients with pain due to a PSNO it was respectively, on average, 70% and
78%. The sensitivity of the DN4-symptoms was, in respect to the gold standard, 70% (95% CI
0.63–0.77) and the specificity was 67% (95% CI 0.54–0.78) (at maximal Youden-index, cut off
point 3/7). Analysis of the DN4-signs solely resulted in an average sensitivity of 75% (95% CI
0.66–0.82) and an average specificity of 75% (95% CI 0.58–0.87) (at maximal Youden-index,
cut off point 1/3). With the outcome based on the grading system the sensitivity was on aver-
age 76% (95% CI 0.68–0.82) and the specificity was 64% (95% CI 0.51–0.74) (at maximal You-
den-index, cut off point 4/10). (Table 6; S2 Table).
In Table 6 and S2 Table we present the number of patients per group, values of the AUC,
Youden index, cut-off score, true positives, false positives, false negatives, true negatives, sensi-
tivity, specificity, positive and negative predictive values, positive and negative likelihood
ratios, the diagnostic odds ratio, the a-priori chance for the existence (or not) of a NePC and
Table 5. The median (IQR) and percentages of the items of the DN4 by physicians agreement of a NePC.
NePC Absent Present Undetermined
N N P N P
Total number of patient 58 170 63
DN4-Symptoms^ Burning 56 12 (21%) 161 77 (48%) 0.001a 57 22 (39%) 0.002a
Painful Cold 54 6 (11%) 154 34 (22%) 0.078a 53 11 (21%) 0.210a
Electric Shocks 55 18 (33%) 162 87 (54%) 0.007a 55 19 (35%) 0.005a
Tingling 55 29 (53%) 160 110 (69%) 0.032a 57 28 (49%) 0.011a
Pins and Needles 52 19 (37%) 157 101 (60%) 0.000a 58 27 (47%) 0.001a
Numbness 54 29 (54%) 165 131 (79%) 0.000a 59 42 (71%) 0.001a
Itching 51 10 (20%) 149 25 (17%) 0.646a 56 14 (25%) 0.409a
DN4-signs^ Hypoesthesia to touch A 42 9 (21%) 153 102 (67%) 0.000a 60 16 (27%) 0.000a
B 41 11 (27%) 151 101 (67%) 0.000a 49 18 (37%) 0.000a
Hypoesthesia to prick A 47 0 (0%) 162 20 (12%) 0.011a 58 3 (5%) 0.017a
B 48 0 (0%) 159 21 (12%) 0.008a 53 1 (2%) 0.002a
Brushing A 43 9 (21%) 157 110 (70%) 0.000a 55 14 (25%) 0.000a
B 43 13 (30%) 151 99 (66%) 0.000a 52 19 (37%) 0.000a
Total sum score DN4 A* (0–10) 47 2 (1–3) 166 5 (3–6) 0.000b 62 3 (2–4) 0.000c
Total sum score DN4 B* (0–10) 48 2 (2–3,75) 159 5 (3–6) 0.000b 56 3 (2–4.75) 0.000c
Total sum score DN4 symptoms* (0–7) 57 2 (1–3) 168 3 (2–5) 0.000b 63 2 (2–4) 0.000c
Total sum score DN4 signs A* (0–3) 49 0 (0–0) 168 2 (1–2) 0.000b 62 0 (0–1) 0.000c
Total sum score DN4 signs B* (0–3) 49 0 (0–1) 161 2 (0–2) 0.000b 56 0 (0–2) 0.000c
Classification for the existence of NePC is based on physicians assessment of the patients. NePC: neuropathic pain component; Absent: NePC is absent;
Present: NePC is present; Undetermined: both physicians disagree with each other about the existence of a neuropathic pain component; N: total number
of patients in analysis; n: number of patients;
^ percentage;
* Inter quartile range. A: physicians A; B: Physicians B; P value for significant difference between groups (P 0.05) by use of different analyse methods:
a: Chi-Squared;
b: Mann-Whitney U test;
c: Kruskal-Wallis test.
https://doi.org/10.1371/journal.pone.0187961.t005
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false positive and negative ratios for all validity outcomes (DN4 A & B, DN4-symptoms,
DN4-signs A & B) divided according to the pain classification and divided into LBLP, NSAP
and PSNO (Table 6 and S2 Table).
Test-retest reliability
Stability and responsiveness of the DN4-symptoms over time was assessed over a period
of two weeks. The median sum score (IQR) of the DN4 at baseline for the total group was 3
(2–4), after two weeks it was 3 (2–4). Taking into consideration the fact that patients’ pain
should not have changed (outcome based on the PGIC) because otherwise the ICC would
not reflect the consistency of the DN4, test-retest reliability via ICC was 0.84 (excellent)
(95%CI 0.80–0.87; n = 265). For the time gap of 7–21 days (to rule out the early or delayed
return of questionnaires) between the first and second DN4-symptoms the ICC was 0.85
(excellent) (95% CI 0.79–0.90; n = 122). After three months, with no change in patients pain
Fig 2. The ROC curve of the DN4, DN4 symptoms and the DN4 signs to the probability of the presence of NePC as
classified based on the assessment by the physicians (A and B). DN4: Doleur Neuropathique en 4 questions;
DN4-symptoms: the items filled in by the patient; DN4 A: DN4-symptoms filled in by the patient and DN4-signs as
asssessed by physicians A; DN4 B: DN4-symptoms filled in by the patient and DN4-signs as asssessed by physicians B;
DN4 signs A: DN4-signs as asssessed by physicians A; DN4 signs B: DN4-signs as asssessed by physicians B.
https://doi.org/10.1371/journal.pone.0187961.g002
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and a time gap of 60–120 days between the first and third DN4-symptoms, ICC was 0.79
(excellent) (95% CI 0.70–0.86; n = 102).
Discussion
The DN4 seems, in this study, to help to identify a neuropathic pain component in a consecu-
tive population of patients with chronic pain in a moderate way.
Reliability
We used the concordant opinion about the classification of patients’ pain by two physicians as
the gold standard. It is disputable if the term gold standard is practicable. However, as written
by Versi[56] [57] “the gold standard is not the perfect test but merely the best available test. . ..
Against which newer tests can be compared”. There are studies regarding the validity of the
DN4 using only one physician’s opinion[21, 30]. To our opinion it is preferable to use two
Table 6. The area under the curve and the sensitivity / specificity at the optimal cut-off point of the DN4 under the condition of equal costs of mis-
classification to classify a neuropathic pain component by the classification and the grading system of the physicians.
Present
NePC
Absent
NePC
AUC (95%CI) Youden
index
Cut-
off
Sens
%
95% CI Spec
%
95% CI PPV
%
NPV PLR 95% CI
Classification
A = B
DN4 A 166 47 0.829 0.767–0.890 0.513 4 75 0.676–0.807 77 0.628–0.864 92 46 3.19 1.889–5.394
LBLP 72 26 0.823 0.738–0.90 0.544 4 74 0.624–0.824 81 0.621–0.915 91 53 3.83 1.72–8.517
NSAP 23 10 0.763 0.576–0.950 0.439 3 74 0.535–0.875 70 0.397–0.892 85 54 2.46 0.927–6.547
PSNO 71 11 0.836 0.713–0.959 0.543 5 63 0.518–0.736 91 0.623–0.984 98 28 6.97 1.067–45.558
DN4 B 159 48 0.807 0.742–0.872 0.498 4 75 0.678–0.81 75 0.612–0.851 91 47 2.99 1.819–4.927
LBLP 67 26 0.821 0.736–0.906 0.554 4 75 0.631–0.835 81 0.621–0.915 91 55 3.88 1.744–8.637
NSP 21 11 0.725 0.529–0.921 0.442 4 71 0.5–0.862 73 0.434–0.903 83 57 2.62 0.961–7.135
PSNO 71 11 0.777 0.644–0.910 0.397 4 76 0.65–0.845 64 0.354–0.848 93 29 2.09 0.947–4.62
DN4-symptoms 168 57 0.713 0.634–0.791 0.369 3 70 0.629–0.766 67 0.537–0.775 86 43 2.11 1.441–3.082
LBLP 74 28 0.716 0.606–0.826 0.348 3 72 0.605–0.806 61 0.424–0.764 83 45 1.82 1.126–2.953
0.348 4 53 0.415–0.637 82 0.644–0.921 89 40 2.95 1.296–6.723
NSAP 23 18 0.661 0.484–0.837 0.374 3 65 0.449–0.812 72 0.491–0.875 75 62 2.35 1.052–5.238
PSNO 71 11 0.764 0.611–0.918 0.431 3 70 0.59–0.798 73 0.434–0.903 94 28 2.58 0.972–6.858
DN4-signs A 168 49 0.781 0.709–0.852 0.537 1 76 0.692–0.82 78 0.641–0.87 92 49 3.39 2.003–5.75
LBLP 73 26 0.744 0.637–0.850 0.479 1 67 0.557–0.768 81 0.621–0.942 91 47 3.49 1.562–7.799
NSAP 23 11 0.783 0.632–0.933 0.565 1 57 0.368–0.744 100 0.741–1.000 100 52 - - - - - -
PSNO 72 12 0.763 0.608–0.917 0.417 1 92 0.83–0.961 50 0.254–0.746 92 50 1.83 1.037–3.242
DN4-signs B 161 49 0.738 0.660–0.816 0.447 1 73 0.66–0.795 71 0.576–0.822 89 45 2.57 1.632–4.033
LBLP 68 26 0.742 0.636–0.847 0.455 1 65 0.528–0.75 81 0.621–0.915 90 47 3.36 1.501–7.541
NSAP 21 11 0.777 0.606–0.948 0.576 1 67 0.454–0.828 91 0.623–0.984 93 59 7.33 1.104–48.691
PSNO 72 12 0.628 0.463–0.794 0.167 1 83 0.731–0.902 33 0.138–0.609 88 25 1.25 0.827–1.89
0.167 2 67 0.552–0.765 50 0.254–0.746 89 20 1.33 0.74–2.403
Grading A = B
DN4 A 138 81 0.771 0.709–0.833 0.396 4 75 0.676–0.818 64 0.533–0.738 78 60 2.10 1.549–2.861
DN4 B 135 75 0.744 0.673–0.814 0.382 4 76 0.677–0.82 63 0.514–0.727 7 59 2.02 1.487–2.755
DN4-symptoms 139 91 0.610 0.537–0.684 0.179 4 45 0.373–0.536 73 0.626–0.806 72 46 1.65 1.128–2.414
DN4-signs A 138 84 0.855 0.803–0.908 0.653 1 86 0.787–0.904 80 0.7–0.87 87 77 4.23 2.748–6.495
DN4-signs B 135 77 0.759 0.691–0.827 0.466 1 78 0.701–0.84 69 0.578–0.781 81 64 2.50 1.769–3.52
DN4: Douleur neuropathique en 4 questions; present NePC: Neuropathic pain component existing; Absent NePC: Neuropathic pain component not
existing; AUC: Area under curve; 95%CI: 95% confidence interval; Sens.: Sensitivity; Spec.: Specificity; PPV: Positive predictive value; A: Physicians A; B:
Physicians B; LBP: Patients suffering from low back and leg pain; NSAP: Patients suffering from neck shoulder arm pain; PSNO: Patients suffering from
pain due to a suspected neuropathic origin.
https://doi.org/10.1371/journal.pone.0187961.t006
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physicians as the gold standard, which is also performed in the original validation study of the
DN4[17]. This might lead to less false positive or false negative outcomes which, of course,
will lead to a more accurate validity outcome. The physicians in this study agreed on pain clas-
sification in 78% of the patients. In other studies without pre-stratification of patients on the
target outcome the results for the physicians agreement were 53%[25] and 89%[27]. The kappa
coefficient between the DN4 as filled in by physician A compared to the DN4 by physician B
was ‘good’ with a high percentage of agreement. Test-retest reliability of the DN4-symptoms
in this study was excellent. Based on these results DN4 seems to be reliable. However, it is pos-
sible that an instrument is reliable without being valid[58].
Validity
To quantify the screening ability of the DN4, for the existence of a NePC, sensitivity and speci-
ficity can be used[59]. However, in clinical practice we want to know many how patients with
a positive score on the DN4 really does have a NePC. To report this, the positive and negative
predictive values are important because they give the proportion of patients with positive or
negative test results which are correctly diagnosed[60]. The predictive value depends on the
prevalence of NePC in the group of patients under study[60]. In our study the prevalence of
NePC was high, 75%. The higher the prevalence of NePC in the group under study the more
sure it is that a positive outcome of the DN4 indicates the presence of a NePC, but the less sure
it is that a negative DN4 outcome indicates absent NePC[60]. The likelihood ratio gives an
indication of the value of the DN4 for increasing certainty about a positive diagnosis[60]. A
higher likelihood ratio might indicate that the DN4 is useful, but is still not sure that a positive
outcome of the DN4 is a good indicator for the presence of a NePC[60]. In the literature there
are, as far as we know, no ‘cut-off’ scores for the validity indices. In our study we found a sensi-
tivity of 75% (DN4-symptoms 70%), a specificity of 76% (DN4-symptoms 67%), positive pre-
dictive value of 92%, negative predictive value of 46% and the positive and negative likelihood
ratios were respectively 3.09 and 0.34. In the original study by Bouhassira et al.[17] patients
with only ‘typical’ neuropathic or nociceptive entities and a VAS of40 mm (0–100mm) were
included. They found a sensitivity of 83% and a specificity of 90%. For the DN4-symptoms the
sensitivity was 78% and the specificity 81%. The Dutch version of the DN4[20] was validated
before in a consecutive group of patients suffering from chronic pain for more than three
months with a pain score of 5 or higher on a 0–10 numeric rating scale (NRS)[25]. For the
DN4 a sensitivity of 75% and a specificity of 79% was found. For the DN4-symptoms version
sensitivity was 74% and the specificity 79%. Van Seventer et al. concluded that the DN4 was a
diagnostic tool with a good ability to discriminate between neuropathic pain and nociceptive
pain[25]. However, the paper by Bouhassira et al.[17] and the paper by Van seventer et al.[25]
both didn’t report the predictive values and likelihood ratios. Inappropriate screening might
result in higher health care costs due to more diagnostic testing or even lead to a harmful treat-
ment for the patient[61]. It seems that the validity indices in our study are resulting in a lower
score for the DN4 as in the original publication[17] and than in other studies[4, 21, 23–28, 30,
31, 62–67]. This might have several reasons. At first, we did not pre-stratify on the target out-
come. In studies, besides the original validation study[17] with pre-stratification on the target
outcome[23, 24, 26, 28, 31] (neuropathic or non-neuropathic pain), the sensitivity of the DN4
was ranging from 90%[26] till 100%[24], the specificity from 93%[24]-97%[23, 28]. In studies
where there was no pre-stratification on the target outcome (neuropathic or non-neuropathic
pain), the sensitivity of the DN4 was ranging from 80%[21] till 100%[30], the specificity ranges
from 78%[21, 27] till 87%[30]. These results are showing that the validity of the DN4 is lower
in studies without pre-stratification than in studies were patients were stratified based on their
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pain classification before entering the study. In studies with specified diseases as spinal cord
injury[64]; diabetes[63, 64]; leprosy[65, 66]; FBSS[67], chronic low back pain[4] and in
patients with cancer before starting with chemotherapy[68], the sensitivity (62%-100%) and
specificity (44%-93%) ranges were much wider. Our results, also when separated into results
for LBLP, NSAP and PSNO, falls within these ranges. This indicates that the neuropathic pain
component is not always clear and/or easy to classify by use of the DN4 in the different medical
conditions. Secondly, in our study we did not have a minimum level of pain as an inclusion
criteria. In seven studies a minimal level of pain (on a rating scale of 0–10) was not an inclu-
sion criteria [21, 23, 31, 62, 63, 65, 66]. In other studies a level three[64, 67], four[4, 17, 24,
26, 28, 30] or five[25, 27] is set as an inclusion criterium. As shown by Perez et al[21], pain
severity has a major influence on the sensitivity and specificity of the DN4. A severity of< 40
mm on a 0-100mm VAS resulted in a sensitivity of 56% and a specificity of 67%. For moderate
pain (between 40mm en 70mm on a 0-100mm VAS) it was 85% and 84% respectively, and
>70 mm sensitivity was 80% and specificity was 74%[21]. In a study by Marksman[67] in
patients after FBSS it was showed that the presence of neuropathic characteristics, as deter-
mined by the DN4, was associated with a higher pain intensity. These facts are crucial for the
validation of a screening instrument because such a tool must be valid for use in daily clinical
out-patient practice and/or for epidemiological purposes.
As a second comparison, we validated the DN4 in comparison with the grading system[32]
[21]. In this study, we combined ‘unlikely’ and possible neuropathic pain as absent NePC and
probable and definite as present NePC, which resulted in an average sensitivity for the DN4 of
76% and an average specificity of 64%. In patients with a failed back surgery syndrome[67],
the validation of the DN4 resulted in a sensitivity of 62% and a specificity of 44%. In a study by
Sadler et al [69] where patients with neuropathic pain were compared to musculoskeletal pain
the sensitivity was 76% and the specificity was 70%. However, in patients with a more mixed
pain the sensitivity and specificity descended to 59% and 70% respectively. Abdallah et al [36]
compared the DN4 with the grading system in patients after breast tumor resection with and
without paravertebral blocks. This resulted in a sensitivity of 90% and a specificity of 60% to
identify patients with chronic neuropathic pain based on the outcome of the grading system.
However, this outcome was not validated by (expert) physicians. The distinction between
possible neuropathic pain and probable or definite neuropathic pain is of high importance
because the outcome forms the basis for selecting a different treatment strategy[34]. The com-
bination of outcomes in our study might have resulted in a lower sensitivity and a bit higher
specificity in comparison with the classification in the study of Abdallah et al[36].
Douleur Neuropathique en 4 questions (DN4). Bouhassira [17] presented the DN4 as a
clinician-administered questionnaire. In different studies not a physician but a research coor-
dinator[30], a nurse[25] or the patient self [25, 70] filled in the DN4. In our study we gave the
patient the questionnaire with the 7-items (DN4-symptoms) to fill them in after the physical
examinations. The three examination-items (DN4-signs) were incorporated in the standard-
ized assessment form which should be filled in by the physician. We presented the DN4 total
sum score as well as the DN4-signs score separately for physicians A and B. This is due to the
fact that it is only possible to have one outcome when the sign-items were performed by one
physician.
Strength and weaknesses
There are several strengths in this study. At first, this study reflects daily clinical practice. In
this study, we included a large cohort of patients irrespective of the predominant origin of the
pain and level of pain which corresponds to a typical daily clinical patient population. These
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patients were associated with the most common specified medical conditions for pain (i.e.
LBLP or NSAP or PSNO) and classified by two, independently working, physicians. Moreover,
patients were referred from primary care to secondary and tertiary pain clinics and were
assessed for their complaints for the first time at the time of inclusion in this study. This limits
the risk of systematic bias and also reflects daily clinical practice. Secondly, we used a standard-
ized assessment form in which the bedside examination and the grading system[32, 33] and
the DN4-signs were incorporated. This might, however, have led to an influence on each other
which made the physician more sure about the final classification of patients pain and thus
made the gold standard stronger. There are also some weaknesses in this study. As said before,
we have not used the DN4-symptoms as a interview by a physician but as a questionnaire
which has to be filled in by the patient. This might have had an influence on the reliability and
validity. In the revised EFNS guidelines on neuropathic pain assessment[42] it is suggested
that “The seven sensory descriptors can be used as a self-report questionnaire with similar
results”. Moreover, above the official Dutch version[20, 25] of the DN4 is written in Dutch:
“To be completed by the patient”. In the paper by van Seventer et al the agreement between
the patient administered and a nurse administered was good till very good for the first seven
items[25]. It would be of interest to see if there are differences in the outcome when the DN4
is filled in by the patient himself or as an interview by the pain physician. Questions by the
patient to the nurse of via telephone to the researcher regarding the DN4 were very rare. How-
ever, we didn’t keep track of the questions. Another limitation is the fact that we only tested
the test-retest reliability regarding the DN4-symptoms and not the DN4-signs to prevent the
patient to come back to the hospital only for these test-items. Another weakness is the gold
standard which is, for now, the best measure for the existence of a neuropathic pain compo-
nent but the result is still open for discussion.
Suggestions for the validation of neuropathic pain screening tools
Validation of screening tools should be performed in a standardized manner and described in
detail, but performed in a setting which is comparable to a daily clinical practice. A research
setting might be different from a clinical setting and thus might have influence on the patient
and on the study results. The group of patients as well as the physicians under study should be
comparable to the patients/physicians for who the tool is intended. Pre-stratification on the
target outcome must be avoided (especially the exclusion of the so called mixed pain), because
this will lead to a non-clinical situation and thus decreases the validity and generalizability of
the instrument[16, 71].
Conclusion
The validity of DN4-signs is equal to the DN4 outcome and, importantly, both are more valid
than the DN4-symptoms alone. It seems that the patients’ symptoms and signs doesn’t reliably
reflect the underlying mechanisms, indicating there is a need for a more objective way to assess
patients’ pain to facilitate improvement in the treatment of patients with pain. The physicians’
assessment cannot be replaced by a screening tool as the DN4, but gives the physician a little
hint towards the (non-)existence of neuropathic pain component.
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S2 Table. The area under the curve and the sensitivity / specificity at the optimal cut-off
point of the DN4 under the condition of equal costs of misclassification to classify a neuro-
pathic pain component by the classification and the grading system of the physicians.
PD-Q: PainDETECT questionnaire; Present NePC: Neuropathic pain component existing;
Absent NePC: Neuropathic pain component not existing; AUC: Area under curve; Std.Error:
Standard error; Asymp. Sig.: Asymptotic Significance; 95%CI: 95% confidence interval; Sens.:
Sensitivity; Spec.: Specificity; +DV: Positive diagnostic value; -DV: Negative diagnostic value;
+LR: Positive likelihood ratio; -LR: Negative likelihood ratio; P[Z+]: a-priori chance for the
existence of a NePC; P[Z-]: a-priori chance for no existence of NePC; FPR: False positive ratio;
FNR: False negative ratio; A: Physician A; B: Physician B; LBLP: Low back and leg pain; NSAP:
Neck shoulder arm pain; PSNO: Pain of suspected neuropathic origin.
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